The “Cetuximab After Progression in KRAS wild-type colorectal cancer patients” (CAPRI) study enrolled KRAS exon 2 wt mCRC patients who received first-line FOLFIRI plus cetuximab, and at progression were randomized to FOLFOX alone or FOLFOX plus cetuximab. The gene discussed is KRAS; the disease is colorectal cancer.